Ximelagatran Versus Warfarin in the Prevention of Atrial Fibrillation–Related Stroke: Both Sides of the Story
| Autor: | Giuseppe Biondi-Zoccai, Pierfrancesco Agostoni, Graziana Trotta, Antonio Abbate, Luca Testa, William J. van Gaal |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Advanced and Specialized Nursing
Secondary prevention medicine.medical_specialty Ximelagatran Stroke etiology business.industry Warfarin Atrial fibrillation Thromboembolic stroke medicine.disease Direct thrombin inhibitor Internal medicine Cardiology Medicine cardiovascular diseases Neurology (clinical) Cardiology and Cardiovascular Medicine business Stroke medicine.drug |
| Zdroj: | Stroke. 38 |
| ISSN: | 1524-4628 0039-2499 |
| Popis: | To the Editor: We have carefully read the interesting article by Akins et al1 focusing on a pivotal issue in the prevention of atrial fibrillation-related stroke. The authors pooled the data from high-risk (previous stroke/TIA) versus nonhigh-risk (no previous stroke/TIA) patients included in SPORTIF III2 and SPORTIF V3 trials in which the direct thrombin inhibitor ximelagatran was compared with warfarin in the primary and secondary prevention of thromboembolic stroke. The authors concluded stating that ximelagatran was at least as effective as warfarin. In our opinion, some points deserve attention and a deeper examination. Our group recently published nonfunded/nonbiased meta-analytic … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|